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Abstract
Background: In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's Disease
Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically important. We examined
how this change compared with measures of clinical meaningfulness.
Methods: This is a secondary analysis of a 12 month open-label study of 100 patients (71 women)
diagnosed with mild to moderate AD treated with 5–10 mg of donepezil daily. We studied the
observed case, 6-month change from baseline on the ADAS-Cog, the Clinician's Interview Based
Impression of Change-Plus Caregiver Input (CIBIC-Plus), patient-Goal Attainment Scaling (PGAS)
and clinician-GAS (CGAS).
Results: At 6 months, donepezil-treated patients (n = 95) were more likely to show no change (+/
- 3 points) on the ADAS-Cog (56%) than to improve (20%) or decline (24%) by 4-points. ADAS-
Cog change scores were little correlated with other measures: from -0.09 for PGAS to 0.27 for
the CIBIC-Plus. While patients who improved on the ADAS-Cog were less likely to decline on the
clinical measures (26%), 43% of patients who declined on the ADAS-Cog improved on at least two
of the clinical measures.
Conclusion: The ADAS-Cog did not capture all clinically important effects. In general, ADAS-Cog
improvement indicates clinical improvement, whereas many people with ADAS-Cog decline do not
show clinical decline. The open-label design of this study does not allow us to know whether this
is a treatment effect, which requires further investigation.
Background
Cholinesterase inhibition is a strategy for treating Alzhe-
imer's disease (AD) that yields statistically significant
though modest cognitive benefits which favour treatment
over placebo[1,2]. The clinical meaningfulness of
cholinesterase inhibition remains controversial [3-7]. A
widely used method of inferring clinical importance is to
classify patients by whether they demonstrate a clinically
meaningful minimal difference on an outcome measure
[8]. The Alzheimer's Disease Assessment Scale-Cognitive
subscale (ADAS-Cog) is the de facto standard primary out-
come neuropsychological measure for AD trials [9]. It
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measures several cognitive domains, including memory,
language and praxis. Total scores range from 0–70, with
higher scores (≥ 18) indicating greater cognitive impair-
ment. Many regulatory authorities recognize a four-point
change on the ADAS-Cog at 6 months as indicating a clin-
ically important difference, a proposal that has impacted
how clinical trials are interpreted [10-13]. Our group was
interested in understanding whether a four-point change
on the ADAS-Cog was reflected in changes on other, more
self-evidently meaningful clinical measures.
Methods
Sample
These data come from a previously reported 12-month,
open label trial of 100 community dwelling, mild-to-
moderate Alzheimer's disease patients (71% women;
average age = 76 years ± 8) treated with donepezil. The
Atlantic Canada Alzheimer's disease Investigation of
Expectations (ACADIE) Study was conducted between
1998–1999 [14,15]. Diagnoses were made using standard
criteria [16,17]. Staging followed the Clinical Dementia
Rating (CDR) scale (mild = 75%) [18]. All patients were
treated with 5 mg/day of donepezil for three months, and
then flexibly dosed at 5 or 10 mg/day. Here, for better
comparison with the 6-month double-blinded trials, we
included only those patients who received treatment for a
minimum of six months. To ensure that we would address
only the meaningfulness of true change, we did not
impute in the case of missing data.
Outcome measures
We compared the 6-month responses on the ADAS-Cog
with those from three judgment-based clinical measures.
The primary outcome was Goal Attainment Scaling
(GAS), used to evaluate patient-centred outcomes [19].
GAS allows clinicians and patients/caregivers to selec-
tively target symptoms, specify desired treatment out-
comes (goals), and evaluate the extent to which these
goals are met. We used a modified GAS approach, setting
goals on a 5-point scale anchored at 0 (baseline) [14]. The
5 points correspond to individualized descriptions of the
pre-treatment state (baseline, recorded as 0), desired
improvements ('somewhat' and 'much' better than base-
line, recorded as +1 and +2), and potential worsening
('somewhat' and 'much' worse, recorded as -1 and -2). For
example, the baseline status (level 0) for a person with a
misplacing problem might be described as follows: mis-
places commonly used items, such as glasses, keys, TV remote,
and wallet as often as 8 times per day and cannot locate items
without verbal direction or hands-on assistance. The goals of
treatment (desired improvements) might be the ability to
find misplaced items without assistance at least once per
day (level +1), and misplacing items fewer than 3 times
per day (+2). Goals can then be weighted or ranked in
order of their relative importance (the most important
goal receives the highest numerical rank). Goal attain-
ment is evaluated by comparing the current status at fol-
low-up with the baseline status and determining where
that outcome should be slotted on the scale; attainment is
recorded as 0 if there has been no change, but is otherwise
scored from -2 to +2. Individual goal scores are summa-
rized for each patient using the following formula: 50 +
{(10∑(wixi))/(0.7(∑wi)2)1/2}, where wi = weight assigned
to the ith goal and xi = score of the ith goal). The summary
score is 50 when all goals remain at the baseline level,
greater than 50 when there is more improvement across
goals than decline, and less than 50 with worsening. In
ACADIE, treatment goals were constructed separately by
clinicians (CGAS) and patients/caregivers (PGAS). Each
was blinded to the goals set by the other. Only patient/car-
egiver goals were weighted (for each CGAS goal, weight =
1). Goals were coded into five domain categories: cogni-
tion, function, behaviour, leisure and social interaction.
Examples of the types of goals that were set for each
domain include: cognition – a decrease in repetitive ques-
tioning, improved word finding, improvement in recent
memory, less misplacing of objects; function – perform-
ing various IADL and ADL tasks with less dependence;
behaviour – less irritability, more initiative; social activi-
ties – outings, especially to scheduled activities such as
church, bingo, card games; leisure – more interest in or
effective performance of hobbies and pastime activities.
The ADAS-Cog was completed independently of the
CGAS, and although patients might have had some idea
as to how they performed on the ADAS-Cog, neither they
nor their caregivers were told of the ADAS-Cog scores.
The Clinician's Interview Based Impression of Change –
Plus Caregiver Input (CIBIC-Plus) was a secondary out-
come [20]. This global assessment of change is based on a
comprehensive, semi-structured, patient/caregiver inter-
view, anchored at 4 ('no change') and ranges from 1–7,
where 1 is "very much improved" and 7 is "very much
worse." Other secondary outcomes included the Mini-
Mental State Examination (MMSE) scored between 0–30
(lower scores indicate greater cognitive decline), the Law-
ton-Brody Physical Self-Maintenance (PSMS) and Instru-
mental Activities of Daily Living (IADL) scales, which
range from 6–30 and 6–31, respectively (higher score
indicate less functional ability), and the Cornell Scale for
Depression in Dementia, with a range of 0–38 (scores
greater than 6 indicate depression) [21-24]. The latter
three measures rely on informants. All measures were
administered at baseline, then every three months up to
12 months.
Analyses
In this exploratory study, we analyzed observed cases
(OC) after 6 months of donepezil therapy. ADAS-Cog
change scores ≤ -4 were equated with improvement,BMC Neurology 2007, 7:26 http://www.biomedcentral.com/1471-2377/7/26
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whereas worsening was defined as a change score ≥ 4.
Scores between 3 and -3 were interpreted as maintenance
of the baseline status (no change). We report the fre-
quency, proportion and baseline characteristics of
patients in each ADAS-Cog response group. Mean change
from baseline, standard deviation and 95% confidence
intervals were calculated for all outcome measures by
ADAS-Cog response group. Between group differences
were tested using chi-square. Spearman correlation coeffi-
cients were calculated to compare mean change on the
ADAS-Cog, as well as the CIBIC-Plus and GAS, with
response on the other outcome measures. Statistical tests
were interpreted at the 5% significance level.
Cut-points were set for each of the judgment based meas-
ures to reflect clinically detectable changes. CIBIC-Plus
improvement was taken as scores of 1–3, and worsening
as 5–7. GAS responses were grouped so that PGAS
improvement was defined as a change > 6 (representing
net improvement in 2/3 of the 8.6 goal areas set on aver-
age by patients and caregivers, and a standardized
response mean of moderate size ~ 0.6), worsening as a
change < -6, and no change as scores between 5 and -5.
Respective CGAS cut-points were set as > 3, < -3 and 2 to -
2, again representing net improvement on most goals, as
clinicians set 3.4 goals on average, and also a standardized
response mean in the moderate range of clinical detecta-
bility. In this way, responses on each of the three judg-
ment-based clinical measures could be cross-classified
against the ADAS-Cog.
Ethics
All patients and caregivers provided written informed
consent. The study protocol was approved by the Research
Ethics Committee of the Queen Elizabeth II Health Sci-
ences Centre, Halifax, Nova Scotia, any by the institu-
tional ethics boards at each participating study centre.
Results
Demographics and baseline characteristics
Ninety-five of 100 patients enrolled at baseline were eval-
uated at 6 months. Five patients had discontinued; three
due to adverse events (diarrhoea n = 2, weight loss n = 1)
and two withdrew consent. The remaining patients
tended to be elderly women with mild AD (Table 1), the
majority of whom (63%) were dosed at 10 mg donepezil
after the initial 3-month follow-up.
ADAS-Cog response at 6 months
The most common response on the ADAS-Cog at 6
months was no change from baseline (56%, mean change
= -0.1, ± 2.0). Patients who showed worsening (24%;
mean change = 8.0, ± 4.7) outnumbered those who had
improved (20%; -6.2, ± 1.7) Patients who improved on
the ADAS-Cog were slightly older than those in the other
response groups, but there was no clear effect of initial
conditions – i.e. those who responded showed no statisti-
cally significant differences from non-responders in base-
line clinical or demographic measures (Table 1).
Comparison of ADAS-Cog response with other outcomes 
at 6 months
The most common response on the patient/caregiver-GAS
(PGAS) at 6 months was no change (i.e., within the range
-3 to + 3) which was twice as common as improvement
(60% versus 31%; Figure 1, Panel A). Overall, the PGAS
response did not correlate well with the ADAS-Cog
response (Table 2). Only 42% of patients, mostly in the
no change/no change group (33%), were similarly classi-
fied by the ADAS-Cog and the PGAS (Figure 1, Panel A).
At a group level, patients with ADAS-Cog improvement
had net improvement on the PGAS (mean change = 7.0 ±
9.1) compared with patients who had ADAS-Cog worsen-
ing (5.4 ± 11.2). At the individual level, however, there
were differences in classification: while no one who was
classified as improved on the ADAS-Cog was rated as hav-
ing worsened clinically, 7/23 people who worsened on
the ADAS-Cog were rated by patient/caregivers as having
improved. This appears to reflect not just the broader
range of domains considered in the PGAS, but also differ-
ing accounts of treatment. For example, considering only
the PGAS-cognition goals (n = 81 patients), a similar pat-
tern obtains (Figure 1, Panel B).
At 6-months, overall responses on the clinic-GAS (CGAS)
tended towards improvement (45%), followed by no
change (32%) and worsening (23%). Mean change from
baseline on the CGAS corresponded with the ADAS-Cog
response by group (from 5.5 ± 9.1 for ADAS-Cog
improved to 0.9 ± 12.4 for ADAS-Cog worsening), but the
correlation between measures was low (Table 2). Here
too, agreement (41%) was concentrated primarily in the
no change/no change group (20%; Figure 2, Panel A).
Patients who improved on the ADAS-Cog were also more
likely to have CGAS improvement (11/19), and again – as
with the PGAS – less agreement was evident with ADAS-
Cog worsening. Of the 23 patients worsened by ≥ 4
points, clinicians rated 9 as improved and 5 as showing
no change. A similar pattern to the PGAS was also seen
when we considered only cognition goals. ADAS-Cog
improvement usually indicates clinical ratings of
improvement or no change; whereas ADAS-Cog worsen-
ing can be seen in many people rated as showing clinical
improvement (Figure 2, Panel B).
In contrast with the ADAS-Cog, the CIBIC-Plus account of
change at 6 months was more evenly distributed: 35%
improved, 31% had no change and 34% worsened (see
Figure 3). For each ADAS-Cog response group, the mean
CIBIC-Plus score changed in the corresponding directionBMC Neurology 2007, 7:26 http://www.biomedcentral.com/1471-2377/7/26
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Table 2: Spearman correlation coefficients comparing mean changes on the ADAS-Cog, CIBIC-Plus, PGAS and CGAS with mean 
changes on other outcomes at 6 months
ADAS-Cog ADAS-Cog ADAS-Cog
improved no change  worsened  ADAS-Cog CIBIC-Plus  PGAS* CGAS*
(n = 19) (n = 53)  (n = 23) (n = 95) (n = 95) (n = 95) (n = 95)
CIBIC-Plus -0.15 0.15 0.38 0.27 1.00
PGAS* 0.40 -0.32 -0.15 -0.09 -0.59 1.00
Cognition* 0.58 -0.50 -0.32 -0.22 -0.60 0.81 0.58
Function* 0.23 -0.25 -0.07 -0.03 -0.27 0.69 0.22
Behaviour* -0.33 0.17 -0.17 -0.06 -0.12 0.47 0.18
Leisure* 0.44 -0.32 -0.15 -0.11 -0.50 0.87 0.36
Social* 0.73 -0.32 -0.50 -0.04 -0.52 0.72 0.39
CGAS* 0.33 -0.09 -0.32 -0.22 -0.77 0.52 1.00
Cognition* 0.41 -0.12 -0.27 -0.21 -0.69 0.51 0.84
Function* 0.36 -0.29 0.20 -0.14 -0.60 0.51 0.77
Behaviour* 0.20 0.35 -0.43 -0.30 -0.72 0.41 0.89
Leisure* -1.00 0.11 0.29 0.12 -0.25 0.32 0.63
Social* 0.15 -0.31 0.21 0.01 -0.76 0.48 0.86
MMSE* 0.59 -0.18 -0.24 -0.35 -0.29 0.24 0.32
PSMS -0.28 0.00 0.37 0.21 0.51 -0.36 -0.53
IADL -0.29 0.16 -0.15 0.11 0.37 -0.27 -0.46
CSD 0.24 -0.03 0.39 0.25 0.40 -0.15 -0.53
*Higher scores indicate better performance (the expected direction is positive), otherwise lower scores indicate improvement.
Table 1: Baseline characteristics of patients with mild-moderate Alzheimer's disease who were treated with donepezil for 6 months, 
by ADAS-Cog response group
All patients  ADAS-Cog ADAS-Cog  ADAS-Cog
(n = 95) improved  no change worsened 
(n = 19) (n = 53) (n = 23)
Baseline characteristics
Females, n (%) 68 (72) 15 (79) 36 (68) 17 (74)
Age, mean years (sd) 75.8 (7.7) 79.8 (8.2) 75.5 (6.3) 73.3 (8.9)
Education, mean years (sd) 11.1 (3.2) 10.5 (3.2) 11.0 (3.2) 11.6 (3.2)
Duration of illness, mean years (sd) 1.3 (1.5) 1.0 (1.0) 1.3 (1.7) 1.5 (1.6)
CDR = mild, n (%) 73 (77) 14 (74) 44 (83) 15 (65)
Baseline outcomes
CIBIS+, mean (sd) 3.7 (0.8) 3.7 (0.8) 3.6 (0.7) 3.9 (0.7)
MMSE, mean (sd) 19.9 (5.3) 20.0 (4.7) 20.6 (5.3) 18.3 (5.4)
ADAS-Cog, mean (sd) 24.6 (9.9) 26.4 (10.6) 23.2 (9.3) 26.3 (10.4)
PSMS, mean (sd) 8.8 (2.5) 9.3 (2.1) 8.8 (2.7) 8.3 (2.2)
IADL, mean (sd) 19.9 (5.4) 20.5 (4.6) 20.1 (5.4) 18.9 (6.1)
CSD, mean (sd) 5.7 (5.4) 6.4 (5.5) 5.5 (5.1) 5.9 (6.2)
Treatment goals set at baseline
PGAS-total, mean (sd) 8.6 (3.3) 8.2 (2.7) 8.7 (3.3) 8.6 (3.8)
PGAS-cognition, mean (sd)1 1.2 (0.8) 1.1 (0.7) 1.2 (0.8) 1.2 (0.7)
CGAS-total, mean (sd) 3.4 (1.3) 3.1 (0.8) 3.5 (1.4) 3.3 (1.2)
CGAS-cognition, mean (sd)2 2.1 (1.8) 2.5 (2.3) 2.2 (1.7) 1.8 (1.4)
1 81/95 patients/caregivers set cognition goals: respectively 16/19, 45/53 and, 20/23
2 81/95 clinicians set cognition goals, respectively 17/19, 45/53 and 19/23BMC Neurology 2007, 7:26 http://www.biomedcentral.com/1471-2377/7/26
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(from 3.6 ± 1.0 for ADAS-Cog improved to 4.2 ± 1.3 for
ADAS-Cog worsening), but the correlation between the
CIBIC-Plus and the ADAS-Cog change scores was low-
moderate (Table 2). Concordance between the CIBIC-
Plus and the ADAS-Cog (i.e., improved on both, no
change on both or worsening on both), occurred in 45%
of patients, mostly in the 22% with no change by either
measure (Figure 3). Clinical impressions showed less var-
iability when the ADAS-Cog indicated improvement than
for any other response. By contrast, 7/23 patients with
Distribution of patients by ADAS-Cog and clinician-GAS  response after 6 months of donepezil therapy Figure 2
Distribution of patients by ADAS-Cog and clinician-
GAS response after 6 months of donepezil therapy. 
Patient responses on the ADAS-Cog at 6 months were cate-
gorized as improved (change from baseline ≤ -4 points), no 
change (-3 to 3) or worsened (≥ 4) and crossed against clini-
cian-GAS (CGAS) improvement (change from baseline ≥ 3), 
no change (-2 to 2) or worsening (≤ -3) for total CGAS goals 
(A) and CGAS cognition goals (B). An asterisk (*) denotes 
agreement between measures – overall 41% for both meas-
ures.
ADAS-Cog response























































Distribution of patients by ADAS-Cog and patient/caregiver- GAS response after 6 months of donepezil therapy Figure 1
Distribution of patients by ADAS-Cog and patient/
caregiver-GAS response after 6 months of donepezil 
therapy. Patient responses on the ADAS-Cog at 6 months 
were categorized as improved (change from baseline ≤ -4 
points), no change (-3 to 3) or worsened (≥ 4) and crossed 
against patient/caregiver-GAS (PGAS) improvement (change 
from baseline ≥ 6), no change (-5 to 5) or worsening (≤ -5) 
for total PGAS goals (A) and PGAS cognition goals (B). An 
asterisk (*) denotes agreement between measures – overall 
42% for total PGAS and 47% for PGAS-cognition.
ADAS-Cog response
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ADAS-Cog deterioration had CIBIC-Plus scores that
showed improvement, including 4 who were rated as
"much" improved (CIBIC-Plus = 2). Most patients (32/53,
60%) characterized as "no change" on the ADAS-Cog
were either improved (n = 16) or worsened (n = 16) on
the CIBIC-Plus.
A small group of patients (15%) demonstrated consist-
ency of response across all measure at 6 months: 5
patients who improved on the ADAS-Cog also improved
on the clinical measures, 8 patients were consistent "no
changers," and 1 patient worsened on all four measures. It
is also notable that when the ADAS-Cog indicated
improvement, only one patient worsened on more than
one clinical measure, whereas 10 patients with ADAS-Cog
worsening showed improvement on at least two of the
three clinical measures (including 6 patients who
improved on all of the clinical measures).
At 6 months, the ADAS-Cog correlated better with the
MMSE than with any other outcome measure (Table 2).
Here, the CIBIC-Plus correlated better than the ADAS-Cog
with all other outcome measures, including PGAS and
CGAS.
Discussion
In this secondary analysis, we investigated the clinical
meaningfulness of a 4-point change on the ADAS-Cog at
6 months. Patients who improved on the ADAS-Cog (n =
19) were unlikely to show clinical deterioration (none by
PGAS, 2 by CGAS, and 4 by CIBIC-Plus), patients with
ADAS-Cog deterioration (n = 23) have a broader range of
clinical outcomes, including about a third (9 by CGAS, 7
by PGAS and 7 by CIBIC-Plus) who show clinically
important improvement. In consequence, it appears that
while such a 4-point ADAS-Cog change at 6 months might
help regulators discriminate treatment effects between
patient groups, a 4-point decline has little inherent clini-
cal meaning for individual patient or physician decision-
making. By contrast, a 4-point improvement more often
signals agreement with physician and patient assessment
of either improvement, or the absence of decline.
Although the "4-point change at 6 months" criterion is
conventional, a recent systematic analysis of double-blind
placebo-controlled trials of cholinesterase inhibitors
demonstrated an average -2.7 point improvement at 6
months and one year [25]. We therefore repeated our
analyses using a "3-point change" criterion at 6 months.
Compared with the 4-point change criterion, this identi-
fied more people as having either improved (29 versus
19) or worsened (30 versus 23). Still, the essential point –
that ADAS-Cog improvement is associated with clinical
improvement whereas many people who decline on the
ADAS-Cog are judged by patients and physicians to have
improved- holds. The data from our study suggests that an
n-point decline on ADAS-Cog needs to be interpreted in
the context of overall response, and should not be privi-
leged over, amongst other considerations, the preferences
of patients and caregivers.
Our data must be interpreted with caution. As this is an
open-label study, we cannot make any inference about
whether these changes are due to treatment, and we have
made no attempt to do so. Such an inference requires pla-
cebo-controlled studies. Where these data can help is in
better understanding whether the commonly-accepted-as-
meaningful 4-point change on the ADAS-Cog has a strong
evidence base. These data make clear that changes at the
group level are not easily translated into changes at the
individual level. This does not mean that the ADAS-Cog
account is right and that the clinical accounts are wrong,
or vice versa. Neither does it gainsay that the ADAS-Cog
shows, at a group level, across trials and across com-
pounds, a dose-response effect which favours the use of
cholinesterase inhibitors, compared with placebo, in peo-
ple with Alzheimer's disease [2]. Nor does it endorse the
view that these effects are meaningless [5]. What it appears
to tell us is that we do need to look carefully at the whole
body of evidence. In short, just as the CIBIC-Plus is a bet-
Distribution of patients by ADAS-Cog and CIBIC-Plus  response after 6 months of donepezil therapy Figure 3
Distribution of patients by ADAS-Cog and CIBIC-
Plus response after 6 months of donepezil therapy. 
Patient responses on the ADAS-Cog at 6 months were cate-
gorized as improved (change from baseline ≤ -4 points), no 
change (-3 to 3) or worsened (≥ 4) and crossed against 
CIBIC-Plus improvement (ratings of 1 to 3), no change (4) or 
worsening (5 to 7). An asterisk (*) denotes agreement 
between measures – overall 45%.
ADAS-Cog response
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ter estimate of decline than of improvement [26], so
might the ADAS-Cog help us estimate the extent of
improvement, but be less good at measuring clinically
meaningful decline.
Another feature of these data is the large proportion of
patients classified as 'no change' by both the ADAS-Cog
and at least one other clinical measure. No change in a
neurodegenerative illness can be a useful goal, but this
needs to be better understood. 'No change' in the CIBIC-
Plus, for example, often appears to reflect clinical trade-
offs [27,28]. Whether there are detectable signals within
the patients classified as no change requires additional
study.
Conclusion
The development of staging tools for untreated Alzhe-
imer's disease, based on natural history observations, was
a labour-intensive process, and took place by carefully
characterizing many patients, often at single sites, over
several years. To attempt the same in the changing envi-
ronment of treatments for Alzheimer's disease is daunting
and may well be impracticable. In the setting of ongoing
clinical studies, however, especially those employing tests
such as the CIBIC-Plus, there is an opportunity to system-
atically record clinical observations in a way that can
quickly allow for some hundreds to be assembled and
compared. If we cannot rely on the ADAS-Cog as a guide
to individual decision-making, we need to pursue other
methods, such as symptom inventories [6,29], to find
more relevant and less arbitrary ways of understanding
treatment effects in individual patients.
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